THE ANTICOAGULANT THERAPY OF HAEMODIALYSIS PATIENTS WITH ACUTE CORONARY SYNDROME

Objectives To evaluate the effect of different dose of anticoagulants in haemodialysis patients with acute coronary syndrome (not including ST-elevate myocardial infarction). Methods 28 patients with ACS (not including ST-elevate myocardial infarction) were enrolled between March 2008 and March 2012 who started haemodialysis for 5–10 years in regular pattern. The patients were randomly divided into two groups: the routine group (n=12) and strengthen group (n=16). All patients were given routine therapy including regular haeparinised haemodialysis (three times a week), rest, oxygen inhaling, antiplatelet, reducing blood lipid levels, controlling the blood pressure. The patients in the routine group were given the factor X a inhibitor fondaparinux 2.5 mg every day except the haemodialysis days. The patients in the strengthen group were given fondaparinux 2.5 mg every day including the haemodialysis days. The course of treatment was 7 days. Observe the symptom, electrocardiogram, cardiac troponin T, coagulation function (PT, APTT, INR) for 14 days. Results One patient in routine group was died of heart failure, another patients in strengthen group exited because of gastrointestinal bleeding. The basic characteristics of the two groups were identical (p>0.05). Patients9 symptom relieved in (3.1±2.8) days in strengthen group and (5.0±3.6) days in routine group (p Conclusions Strengthen anticoagulant therapy in haemodialysis patients with acute coronary syndrome (not including ST-elevate myocardial infarction) is more effective than routine therapy, but we must be care of the risk of haemorrhage.